Chronic Kidney Disease Pipeline Insight 2025

Strategic Insights -

DelveInsight's report on Chronic Kidney Disease provides comprehensive insights into the 80+ active players working to develop 85+ pipeline therapies for Chronic Kidney Disease treatment. The report covers the pipeline drug profiles, including clinical and nonclinical stage products, and analyzes the key companies involved in targeted therapeutics development. It also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease treatment.

Key Takeaways:

  • Over 80 major companies are actively developing treatments for Chronic Kidney Disease (CKD), with Novo Nordisk advancing its drug candidates to the furthest stage of development-Phase III clinical trials.
  • The report covers around 85+ products under different phases of clinical development, including late-stage products (Phase III), mid-stage products (Phase II), and early-stage product (Phase I).
  • Key companies such as Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata Therapeutics, Unicycive Therapeutics, Novo Nordisk, Bayer, AstraZeneca, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Boehringer Ingelheim, SCOHIA PHARMA, Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Disc Medicine, Shandong Suncadia Medicine, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Healx, Benevolent, and others are evaluating new drugs for Chronic Kidney Disease to improve the treatment landscape.
  • Promising Chronic Kidney Disease pipeline therapies in various stages of development include Ziltivekimab, Rilparencel, US-APR2020, XRx-008, CLBS201, UNI-494, and others.
  • The report provides detailed insights into the key companies that are developing therapies in the Chronic Kidney Disease Market, and it analyzes the key players involved in targeted therapeutics development.
  • The report evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease treatment.

Statistics:

  • 80+ key companies are actively developing treatments for Chronic Kidney Disease (CKD).
  • 85+ pipeline therapies are in development for Chronic Kidney Disease treatment.
  • Novo Nordisk has advanced its drug candidates to the furthest stage of development-Phase III clinical trials.
  • More than 40 companies are in collaboration, partnership, or licensing agreement for developing Chronic Kidney Disease treatments.
  • The Global Chronic Kidney Disease market size is expected to increase in the future due to the growth in the number of patients suffering from the disease and the increasing awareness about the treatment options available.

Sources:

  • DelveInsight's report on Chronic Kidney Disease.
  • Unicycive Therapeutics (Nasdaq: UNCY) press release dated November 2024.
  • Boehringer Ingelheim press release dated March 2023.
  • M2 PressWIRE press release dated July 9, 2025.